Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
September 10, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology to Host First Virtual Investor Day on September 26, 2024

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...
September 04, 2024 16:30 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
August 27, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology to Present at Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
August 13, 2024 07:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On...
August 02, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
July 31, 2024 07:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
July 02, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
June 05, 2024 16:15 ET | Source: Mural Oncology, Inc.

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
June 04, 2024 16:00 ET | Source: Mural Oncology, Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...